Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Questcor Pharmaceuticals Inc (QCOR): What Is the “True” Intention Behind This Market-Moving Drug Acquisition?

Synacthen has already been granted an Orphan designation, and in biotechnology, it needs nothing more in order to demand premium pricing. Synacthen is already being used to treat many of Questcor’s more lucrative indications in other countries. Therefore, Questcor might find it simple to boost the price of Synacthen, once it’s approved, and then use it as an alternative to Acthar in treating common diseases in which Acthar has no effect.

If Questcor’s plan is to eventually boost the price of Synacthen – based on its history I see no reason to believe that this is not their intention – then it seems logical that large pharma Novartis would want no part in the launch. A small royalty on inflated revenue would be more lucrative for the company versus marketing at just 3% the price of Acthar. At this point, it’s hard to say with certainty if Questcor will go this route – but with all things considered, it does seem like the only logical explanation for the acquisition.

Final thoughts

While Questcor Pharmaceuticals Inc (NASDAQ:QCOR)’s business practices may be frowned upon, they are not unheard of in biotechnology. As an investor, when you can find such a practice it is usually very rewarding.

Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) has practiced the same strategy for the last five years, and during this period its stock has increased over 8,000%. Specifically, its drug Xyrem – which treats rare conditions – has seen a price hike of 220% since late 2008. Moreover, analysts expect another 70% boost by the end of 2014. However, there is a difference between it and Questcor: Jazz Pharmaceuticals actively markets 10 other drugs. Furthermore, Jazz has been lessening its dependence on Xyrem through acquisitions and pipeline growth; a practice that Questcor might need to explore.

While Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) is playing the Questcor game (partially), they are nowhere near as good as Questcor. In history, there is perhaps no other company that has been as successful at boosting prices and maintaining insurance coverage. As a result, I find it hard to believe that Questcor’s strategy is not to try the same strategy with Synacthen, and to see if it can go two-for-two.

Brian Nichols has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Brian is a member of The Motley Fool Blog Network — entries represent the personal opinion of the blogger and are not formally edited.

The article What Is the “True” Intention Behind This Market-Moving Drug Acquisition? originally appeared on Fool.com and is written by Brian Nichols.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.